Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brett P Monia

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
Science Translational Medicine|November 20, 2015
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerDavid Hong, Razelle Kurzrock, Youngsoo Kim, et al.
Neurology and Therapy|February 27, 2021
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L<sub>Rx</sub> (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid PolyneuropathyTeresa Coelho, Yukio Ando, Merrill D Benson, et al.
Journal for Immunotherapy of Cancer|November 18, 2018
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J Reilley, Patricia McCoon, Carl Cook, et al.
The Journal of Clinical Investigation|June 3, 2004
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitorsKyle W Sloop, Julia Xiao-Chun Cao, Angela M Siesky, et al.
Science Translational Medicine|May 13, 2021
An oral antisense oligonucleotide for PCSK9 inhibitionPeter Gennemark, Katrin Walter, Niclas Clemmensen, et al.
The New England Journal of Medicine|July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
Science Translational Medicine|November 20, 2015
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerDavid Hong, Razelle Kurzrock, Youngsoo Kim, et al.
Neurology and Therapy|February 27, 2021
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L<sub>Rx</sub> (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid PolyneuropathyTeresa Coelho, Yukio Ando, Merrill D Benson, et al.
Journal for Immunotherapy of Cancer|November 18, 2018
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J Reilley, Patricia McCoon, Carl Cook, et al.
The Journal of Clinical Investigation|June 3, 2004
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitorsKyle W Sloop, Julia Xiao-Chun Cao, Angela M Siesky, et al.
Science Translational Medicine|May 13, 2021
An oral antisense oligonucleotide for PCSK9 inhibitionPeter Gennemark, Katrin Walter, Niclas Clemmensen, et al.
The New England Journal of Medicine|July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
Pageof 15